PPD, which already has offices in Moscow, Smolensk and St Petersburg, intends to strengthen its presence in Russia with this new office.
PPD is a contract research organisation (CRO), providing drug discovery, development and lifecycle management services to pharmaceutical, biotechnology, medical device, academic and government organisations.
PPD Europe, Middle East and Africa clinical development vice president Roger Newbery said that establishing a presence in Novosibirsk allows them to serve clients more effectively and keep pace with clinical trial growth in this region.